MigraineMind research summary
Calcitonin Gene-Related Peptide Monoclonal Antibody Utilization and Treatment Gaps in People with Migraine in Japan: Results from the OVERCOME (Japan) 2nd Study.
Drugs Real World Outcomes | 2026
Observational studySummary
Calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) effectively prevent migraines. However, their use in Japan remains low. The OVERCOME (Japan) 2nd study analyzed CGRP mAb utilization patterns and treatment gaps. The study surveyed adults with migraines across Japan. It classified respondents based on CGRP mAb eligibility. Among 19,590 respondents, 1,484 (8%) met the eligibility criteria. Of these, only 78 were current CGRP mAb users, while 1,348 never used them. Most eligible individuals had not received CGRP mAb therapy. Among ineligible respondents, 110 used CGRP mAbs and 17,820 never did. Those with CGRP mAb experience had higher consultation rates with specialists. Most current users had consulted headache specialists (40%). Awareness of CGRP mAbs was low, with 78% unaware. Additionally, only 4% were informed by physicians. This indicates a significant treatment gap among eligible migraine sufferers in Japan. Improving awareness and access to specialists is essential for better treatment. Clinical relevance: This research highlights the need to improve awareness and access to CGRP mAbs for migraine patients in Japan.
Key Learning Points
- CGRP monoclonal antibodies are effective in preventing migraines but are underutilized in Japan.
- Only 8% of surveyed individuals with migraines were eligible for CGRP mAb therapy, highlighting a significant treatment gap.
- Among those eligible for treatment, only 5% were actually using CGRP mAbs, indicating low adoption rates.
- Most migraine sufferers are unaware of CGRP mAbs, with 78% lacking knowledge about these treatments.
- Consulting a headache specialist increases the likelihood of using CGRP mAbs, emphasizing the importance of specialist access.
Related migraine research topics
Original research
Read the original publication and review its full methods and findings on PubMed.
MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.